Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Introduction: Alternation of osimertinib and afatinib is a potential approach to overcome osimertinib resistance and to allow complementation of drug efficacy without compromising safety in patients with epidermal growth factor receptor gene (EGFR)–mutated non–small cell lung cancer (NSCLC). Methods...

Full description

Bibliographic Details
Main Authors: Azuma, K. (Author), Chiba, Y. (Author), Daga, H. (Author), Fujimoto, D. (Author), Hataji, O. (Author), Hayashi, H. (Author), Hirano, K. (Author), Ikeda, S. (Author), Nakagawa, K. (Author), Nakamura, A. (Author), Nishio, K. (Author), Okada, H. (Author), Sakai, K. (Author), Sakata, S. (Author), Tachihara, M. (Author), Yamamoto, N. (Author), Yano, Y. (Author), Yokoyama, T. (Author), Yonesaka, K. (Author)
Format: Article
Language:English
Published: Elsevier Ireland Ltd 2022
Subjects:
Afatinib
Epidermal growth factor receptor (EGFR)
Non-small cell lung cancer (NSCLC)
Osimertinib
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items